Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge

<b>Background:</b> Assessing pancreatic ductal adenocarcinoma (PDAC) resectability after neoadjuvant therapy (NAT) remains a diagnostic challenge. Traditional computed tomography (CT) criteria often fail to distinguish viable tumor from fibrosis, necessitating a reassessment of imaging-b...

Full description

Saved in:
Bibliographic Details
Main Authors: Ioannis Christofilis, Charikleia Triantopoulou, Spiros Delis
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/15/14/1810
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849734123470454784
author Ioannis Christofilis
Charikleia Triantopoulou
Spiros Delis
author_facet Ioannis Christofilis
Charikleia Triantopoulou
Spiros Delis
author_sort Ioannis Christofilis
collection DOAJ
description <b>Background:</b> Assessing pancreatic ductal adenocarcinoma (PDAC) resectability after neoadjuvant therapy (NAT) remains a diagnostic challenge. Traditional computed tomography (CT) criteria often fail to distinguish viable tumor from fibrosis, necessitating a reassessment of imaging-based standards. <b>Methods:</b> A comprehensive literature review was conducted using PubMed, focusing on prospective and retrospective studies over the past 25 years that evaluated the role of CT and complementary imaging modalities (MRI, PET-CT) in predicting resectability post-NAT in non-metastatic PDAC. Studies with small sample sizes or case reports were excluded. <b>Results:</b> Across studies, conventional CT parameters—particularly >180° vascular encasement—showed a limited correlation with histologic invasion or surgical outcomes after NAT. Persistent vessel contact on CT often reflected fibrosis, rather than active tumor. Dynamic changes, such as regression in the tumor–vessel interface and vessel lumen restoration, correlated more accurately with R0 resection. Adjunct markers like CA 19-9 response and patient performance status further improved resectability prediction. <b>Conclusions:</b> CT-based resectability assessment after NAT should transition from static morphologic criteria to response-based interpretation. Multidisciplinary evaluation integrating radiologic, biochemical, and clinical findings is essential to guide surgical decision-making and improve patient outcomes.
format Article
id doaj-art-34e4843d530749258e6c83f4332e5d48
institution DOAJ
issn 2075-4418
language English
publishDate 2025-07-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj-art-34e4843d530749258e6c83f4332e5d482025-08-20T03:07:54ZengMDPI AGDiagnostics2075-44182025-07-011514181010.3390/diagnostics15141810Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging ChallengeIoannis Christofilis0Charikleia Triantopoulou1Spiros Delis2Radiology Department, Konstantopouleio Hospital, 142 33 Athens, GreeceRadiology Department, Konstantopouleio Hospital, 142 33 Athens, GreeceHPB Unit, Konstantopouleio Hospital, 142 33 Athens, Greece<b>Background:</b> Assessing pancreatic ductal adenocarcinoma (PDAC) resectability after neoadjuvant therapy (NAT) remains a diagnostic challenge. Traditional computed tomography (CT) criteria often fail to distinguish viable tumor from fibrosis, necessitating a reassessment of imaging-based standards. <b>Methods:</b> A comprehensive literature review was conducted using PubMed, focusing on prospective and retrospective studies over the past 25 years that evaluated the role of CT and complementary imaging modalities (MRI, PET-CT) in predicting resectability post-NAT in non-metastatic PDAC. Studies with small sample sizes or case reports were excluded. <b>Results:</b> Across studies, conventional CT parameters—particularly >180° vascular encasement—showed a limited correlation with histologic invasion or surgical outcomes after NAT. Persistent vessel contact on CT often reflected fibrosis, rather than active tumor. Dynamic changes, such as regression in the tumor–vessel interface and vessel lumen restoration, correlated more accurately with R0 resection. Adjunct markers like CA 19-9 response and patient performance status further improved resectability prediction. <b>Conclusions:</b> CT-based resectability assessment after NAT should transition from static morphologic criteria to response-based interpretation. Multidisciplinary evaluation integrating radiologic, biochemical, and clinical findings is essential to guide surgical decision-making and improve patient outcomes.https://www.mdpi.com/2075-4418/15/14/1810pancreatic cancerneoadjuvant therapycomputed tomographyresectabilityvascular involvementimaging biomarkers
spellingShingle Ioannis Christofilis
Charikleia Triantopoulou
Spiros Delis
Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge
Diagnostics
pancreatic cancer
neoadjuvant therapy
computed tomography
resectability
vascular involvement
imaging biomarkers
title Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge
title_full Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge
title_fullStr Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge
title_full_unstemmed Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge
title_short Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge
title_sort pancreatic cancer resectability after neoadjuvant treatment an imaging challenge
topic pancreatic cancer
neoadjuvant therapy
computed tomography
resectability
vascular involvement
imaging biomarkers
url https://www.mdpi.com/2075-4418/15/14/1810
work_keys_str_mv AT ioannischristofilis pancreaticcancerresectabilityafterneoadjuvanttreatmentanimagingchallenge
AT charikleiatriantopoulou pancreaticcancerresectabilityafterneoadjuvanttreatmentanimagingchallenge
AT spirosdelis pancreaticcancerresectabilityafterneoadjuvanttreatmentanimagingchallenge